ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Cancer Program Advocates, Success Overcame Powerful Negative Factors To Win Budget Fight

August 10, 1979

Clinical Trials Approved By NCI During November Are Listed

December 27, 2002

FDA Concerned About Data-Dredging In Drug-Diagnostic Applications

January 30, 2009

Chabner Criticizes FDA Crackdown On Off-Label Info

June 28, 1991

FDA Approves Avastin Combination For Late-Stage Cervical Cancer

August 29, 2014

In Brief: CDP Awarded Contract To Do Facilities Survey; MIHICH Appointment Official; Kraybill Retires

August 24, 1984